Dr. Barry Dworkin

First step studying the outcomes of a one-and-done therapy using pegylated interferon lambda demonstrated that it helped curb severe COVID-19 infection-related hospitalizations.

Medical Mythbusting Commentary for February 9, 2023

Source:
New one-and-done therapy can help curb severe COVID-19 infection: Canadian-led study

Reference:
Early Treatment with Pegylated Interferon Lambda for Covid-19

Related posts:

  1. Unpublished, uncontrolled small study claims that experimental exosome treatment shortens recovery time to five days for patients with severe Covid-19. Further human trials required to prove it truly works.
  2. UBC, Université de Sherbrooke, and Cornell University researchers report a new enzyme-blocking compound delivered in a nasal spray that effectively treats delta variant infection in mice. Human trials dependent on securing funding.
  3. Study shows ten percent of people, mostly men, with severe COVID-19, develop an autoimmune response that attacks interferons (part of the immune system) thereby reducing the host’s ability to defend against the virus.
  4. Researchers start the trek to figure out the biological mechanism how COVID infections lead to autoimmune disease even after recovery. First clues found that may lead to understanding Long-COVID. More to come. #GoScience #VaccinesWork